Green Brook, NJ, United States of America

Rongze Kuang

USPTO Granted Patents = 23 (Patent Applications = 6)

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 15 (Patent Applications = 19)

Average Co-Inventor Count = 13.5

ph-index = 3

Forward Citations = 39(Granted Patents)

Company Filing History:

21 out of 2,405

Merck Sharp + Dohme Corp.

Albany Molecular Research, Inc.

patents

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

23 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12466831 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-11-11),

2. 12459927 - Plasma kallikrein inhibitors (2025-11-04),

3. 12428397 - Factor XI activation inhibitors (2025-09-30),

4. 12414952 - Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use (2025-09-16),

5. 12304899 - Factor XI activation inhibitors (2025-05-20),

6. 11046714 - 2,2-difluorodioxolo Areceptor antagonists (2021-06-29),

7. 10822338 - Substituted aminoquinazoline compounds as Aantagonist (2020-11-03),

8. 10472347 - Aminopyrazine compounds with A2A antagonist properties (2019-11-12),

9. 10143681 - Factor XIa inhibitors (2018-12-04),

10. 10138212 - [object Object] (2018-11-27),

11. 10081617 - Factor XIa inhibitors (2018-09-25),

12. 10011615 - Heterobicyclo-substituted [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with A2A anatagonist properties (2018-07-03),

13. 10011585 - Factor XIa inhibitors (2018-07-03),

14. 9868727 - Factor XIa inhibitors (2018-01-16),

15. 9783530 - Factor Xla inhibitors (2017-10-10),

Title: The Innovative Journey of Rongze Kuang

Introduction

Rongze Kuang, based in Green Brook, NJ, has made significant contributions to the field of pharmaceuticals and medicinal chemistry. With an impressive portfolio of 19 patents, his work focuses on developing innovative solutions for various medical challenges, including thromboses and neurological disorders.

Latest Patents

Among his notable patents, Rongze has recently developed selective Factor XI activation inhibitors, which offers a promising approach in treating or preventing thromboses, embolisms, hypercoagulability, and fibrotic changes. His compounds, outlined in the patent, are designed to effectively manage conditions related to abnormal blood coagulation.

Additionally, he has patented 2,2-difluorodioxolo compounds that act as antagonists of Areceptor. This invention is particularly relevant for addressing neurological disorders and diseases linked to Areceptor dysfunction. The pharmaceutical compositions derived from these compounds hold potential for both treatment and prevention of such conditions.

Career Highlights

Rongze Kuang has built a robust career working with renowned pharmaceutical companies. Notably, he has been associated with Merck Sharp & Dohme Corporation and Schering Corporation. His experience in these institutions has contributed greatly to his innovative capabilities and patent portfolio.

Collaborations

Throughout his career, Rongze has collaborated with esteemed colleagues, including Pauline C. Ting and Heping Wu. These partnerships have fostered an environment of creativity and shared knowledge, leading to the advancement of various pharmaceutical innovations.

Conclusion

With 19 patents to his name and a strong background in pharmaceutical research, Rongze Kuang stands out as a notable inventor in the field. His work on Factor XI activation inhibitors and Areceptor antagonists not only showcases his innovative mindset but also holds promise for future medical advancements.

This text is generated by artificial intelligence and may not be accurate.